Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Human Genome Sciences GlaxoSmithKline |
---|---|
Information provided by: | Human Genome Sciences |
ClinicalTrials.gov Identifier: | NCT00712933 |
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
Condition | Intervention | Phase |
---|---|---|
Systemic Lupus Erythematosus |
Drug: belimumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 |
Estimated Enrollment: | 1620 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
1 mg/kg dose of belimumab given IV every 28 days.
|
Drug: belimumab
Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days. |
2.: Experimental
10 mg/kg dose of belimumab given IV every 28 days.
|
Drug: belimumab
Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days. |
This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | William Freimuth, MD, PhD | Human Genome Sciences, Inc. |
Responsible Party: | Human Genome Sciences, Inc. ( William Freimuth, MD, PhD/Vice President, Clinical Research Immunology, Rheumatology & Infectious Diseases ) |
Study ID Numbers: | HGS1006-C1074 |
Study First Received: | July 8, 2008 |
Last Updated: | December 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00712933 |
Health Authority: | United States: Food and Drug Administration; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Brazil: Ministry of Health; Chile: Instituto de Salud Publica de Chile; India: Ministry of Health; Romania: National Medicines Agency; Korea: Food and Drug Administration; Taiwan: Department of Health; Philippines: Department of Health; Australia: National Health and Medical Research Council; Hong Kong: Department of Health; Russia: Ministry of Health and Social Development of the Russian Federation; Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos; Peru: General Directorate of Pharmaceuticals, Devices, and Drugs; Canada: Health Canada; Mexico: Ministry of Health; Germany: Paul-Ehrlich-Institut; Belgium: Ministry of Social Affairs, Public Health and the Environment; Netherlands: Independent Ethics Committee; Czech Republic: State Institute for Drug Control; Slovakia: State Institute for Drug Control; United Kingdom: Department of Health; Spain: Ministry of Health; Poland: Ministry of Health; Italy: Ministry of Health; Austria: Agency for Health and Food Safety; Israel: Ministry of Health; Sweden: Medical Products Agency |
SLE Lupus Systemic Lupus Erythematosus |
Antibodies Autoimmune Diseases Belimumab |
Antibodies, Monoclonal Antibodies Autoimmune Diseases |
Lupus Erythematosus, Systemic Connective Tissue Diseases Immunoglobulins |
Immune System Diseases |